Respiratory Syncytial Virus Vaccination in Older Adults: Considerations for Use and Shared Clinical Decision-Making.

IF 1.1 4区医学 Q4 GERIATRICS & GERONTOLOGY

Journal of gerontological nursing Pub Date : 2024-03-01 DOI:10.3928/00989134-20240207-02

Morgan A Gerber, Michael K Burke, Michael R Brodeur

{"title":"Respiratory Syncytial Virus Vaccination in Older Adults: Considerations for Use and Shared Clinical Decision-Making.","authors":"Morgan A Gerber, Michael K Burke, Michael R Brodeur","doi":"10.3928/00989134-20240207-02","DOIUrl":null,"url":null,"abstract":"Purpose: To evaluate the impact of two newly U.S. Food and Drug Administration-approved respiratory syncytial virus (RSV) vaccines, RSVpreF3 (Arexvy™, GSK) and RSVpreF (Abrysvo™, Pfizer), on morbidity in older adults. RSV is known to cause significant health issues in this demographic.Method: The current article reviews Phases 1 and 2 and Phase 3 published clinical trials, the recommendations for immunization practices outlined in the Morbidity and Mortality Weekly Report, and other relevant literature on RSV infection and vaccine coadministration. A case vignette is also included to illustrate an example of the shared clinical decision-making process for vaccination.Results: Findings suggest that RSVpreF3 and RSVpreF vaccines effectively reduce health complications of RSV in older adults. Successful integration of these vaccines with other immunizations is also highlighted, emphasizing the role of an interprofessional team in this process.Conclusion: The introduction of RSVpreF3 and RSVpreF vaccines represents a significant advancement in the management of RSV in older adults. This article underscores the importance of shared clinical decision-making in vaccine administration and the effective coordination of an interprofessional team for coadministration with other vaccines. [Journal of Gerontological Nursing, 50(3), 7-12.].","PeriodicalId":15848,"journal":{"name":"Journal of gerontological nursing","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of gerontological nursing","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3928/00989134-20240207-02","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"GERIATRICS & GERONTOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To evaluate the impact of two newly U.S. Food and Drug Administration-approved respiratory syncytial virus (RSV) vaccines, RSVpreF3 (Arexvy™, GSK) and RSVpreF (Abrysvo™, Pfizer), on morbidity in older adults. RSV is known to cause significant health issues in this demographic.

Method: The current article reviews Phases 1 and 2 and Phase 3 published clinical trials, the recommendations for immunization practices outlined in the Morbidity and Mortality Weekly Report, and other relevant literature on RSV infection and vaccine coadministration. A case vignette is also included to illustrate an example of the shared clinical decision-making process for vaccination.

Results: Findings suggest that RSVpreF3 and RSVpreF vaccines effectively reduce health complications of RSV in older adults. Successful integration of these vaccines with other immunizations is also highlighted, emphasizing the role of an interprofessional team in this process.

Conclusion: The introduction of RSVpreF3 and RSVpreF vaccines represents a significant advancement in the management of RSV in older adults. This article underscores the importance of shared clinical decision-making in vaccine administration and the effective coordination of an interprofessional team for coadministration with other vaccines. [Journal of Gerontological Nursing, 50(3), 7-12.].

查看原文本刊更多论文

老年人接种呼吸道合胞病毒疫苗：使用和共同临床决策的注意事项。

目的：评估美国食品和药物管理局新批准的两种呼吸道合胞病毒（RSV）疫苗 RSVpreF3（Arexvy™，葛兰素史克）和 RSVpreF（Abrysvo™，辉瑞）对老年人发病率的影响。众所周知，RSV 会给这一人群带来严重的健康问题：本文回顾了已公布的第 1 期、第 2 期和第 3 期临床试验、《发病率与死亡率周报》中概述的免疫实践建议，以及 RSV 感染和联合接种疫苗的其他相关文献。报告还包括一个案例，以说明疫苗接种的共同临床决策过程：结果：研究结果表明，RSVpreF3 和 RSVpreF 疫苗能有效减少老年人 RSV 的并发症。结果：研究结果表明，RSVpreF3 和 RSVpreF 疫苗可有效减少老年人 RSV 的并发症，同时还强调了这些疫苗与其他免疫接种的成功结合，强调了跨专业团队在此过程中的作用：结论：RSVpreF3 和 RSVpreF 疫苗的引入代表了老年人 RSV 管理方面的重大进步。这篇文章强调了在疫苗接种过程中共同临床决策的重要性，以及跨专业团队在与其他疫苗联合接种时进行有效协调的重要性。[老年护理杂志》，50（3），7-12]。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of gerontological nursing 医学-护理

CiteScore

2.00

自引率

7.70%

发文量

审稿时长

6-12 weeks

期刊介绍： The Journal of Gerontological Nursing is a monthly, peer-reviewed journal publishing clinically relevant original articles on the practice of gerontological nursing across the continuum of care in a variety of health care settings, for more than 40 years.